Article
A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
Cancer medicine - 1 Aug 2023
Sun Wei, Xu Yu, Yan WangJun, Wang ChunMeng, Hu Tu, Luo ZhiGuo, Zhang XiaoWei, Liu Xin, Chen Yong
Abstract excerpt
BACKGROUND: Melanoma frequently harbors BRAF, NRAS, or KIT mutations which influence both tumor development and treatment strategies. For example, it is still controversial whether adjuvant anti-PD-1 monotherapy or BRAF/MEK inhibitors may better improve the survival for resected BRAF-mutant melanoma. Furthermore, outcomes for melanoma with NRAS and KIT mutation receiving adjuvant immunotherapy remain unclear....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.